Sg3 Management, LLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $78,900 - $178,800	-10,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $231,200 - $395,200	-20,000 Reduced 66.67%	10,000 $163,000
Q4 2021 Feb 15, 2022	BUY	$11.18 - $15.46 $72,670 - $100,490	6,500 Added 27.66%	30,000 $416,000
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $333,935 - $414,774	23,500 New	23,500 $338,000
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $285,000 - $517,199	-30,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $552,750 - $1.02 Million	-75,000 Reduced 71.43%	30,000 $305,000
Q3 2020 Nov 13, 2020	BUY	$3.43 - $5.53 $360,150 - $580,650	105,000 New	105,000 $361,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.